Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
In recent years, the patients with IB2 and IIA2 stage cervical cancer are still treated with
radiotherapy and chemotherapy based treatment, but the radiotherapy will severely damage the
function of ovary, cause endocrine dyscrasia and the sexual function of vagina. So we want to
study whether neoadjuvant chemotherapy without radiotherapy will achieve the same outcome
compared with traditional therapy including radiotherapy. So we randomly divide IB2 and IIA2
stage cervical cancer patients into two groups. The neoadjuvant chemotherapy group will
receive two courses of chemotherapy basically composed of platinum, and then undergo surgery,
after that, doctors will add more courses of chemotherapy according to the situations of the
patients, including whether the patients have the adverse prognostic factors. The control
group will undergo surgery directly, and then receive chemotherapy and radiotherapy at the
same time. Then we will compare the outcomes of these two groups, and analyze the therapeutic
effect, the impact on survival rate and the effect on improving the living quality of patient
from two groups. All the outcomes will be fed back to clinical doctors and instruct them to
choose better treatment for patients.